Natural Health Science News The latest news and top resources on natural health.

Vaccinations – Safety

Posted October 4, 2018

Parental vaccine safety concerns. The experiences of pediatricians and family physicians.

Freed, G. L., S. J. Clark, B. F. Hibbs, and J. M. Santoli. “Parental Vaccine Safety Concerns. The Experiences of Pediatricians and Family Physicians.” [In eng]. Am J Prev Med 26, no. 1 (Jan 2004): 11-4.

Tracking Vaccine-Safety Inquiries to Detect Signals and Monitor Public Concerns.

Miller, E., B. Batten, L. Hampton, S. R. Campbell, J. Gao, and J. Iskander. “Tracking Vaccine-Safety Inquiries to Detect Signals and Monitor Public Concerns.” [In eng]. Pediatrics 127 Suppl 1 (May 2011): S87-91.

White Paper on studying the safety of the childhood immunization schedule in the Vaccine Safety Datalink.

Glanz, J. M., S. R. Newcomer, M. L. Jackson, S. B. Omer, R. A. Bednarczyk, J. A. Shoup, F. DeStefano, and M. F. Daley. “White Paper on Studying the Safety of the Childhood Immunization Schedule in the Vaccine Safety Datalink.” [In eng]. Vaccine 34 Suppl 1 (Feb 15 2016): A1-A29.

Adoption of Rotavirus Vaccine by U.S. Physicians Progress and Challenges.

O’Leary, S. T., U. D. Parashar, L. A. Crane, M. A. Allison, S. Stokley, B. L. Beaty, M. Brtnikova, L. P. Hurley, and A. Kempe. “Adoption of Rotavirus Vaccine by U.S. Physicians: Progress and Challenges.” [In eng]. Am J Prev Med 44, no. 1 (Jan 2013): 56-62.

Parental vaccine safety concerns – Results from the National Immunization Survey, 2001-2002.

Allred, N. J., K. M. Shaw, T. A. Santibanez, D. L. Rickert, and J. M. Santoli. “Parental Vaccine Safety Concerns: Results from the National Immunization Survey, 2001-2002.” [In eng]. Am J Prev Med 28, no. 2 (Feb 2005): 221-4.

Pediatricians’ experience with and response to parental vaccine safety concerns and vaccine refusals: a survey of Connecticut pediatricians.

Leib, S., P. Liberatos, and K. Edwards. “Pediatricians’ Experience with and Response to Parental Vaccine Safety Concerns and Vaccine Refusals: A Survey of Connecticut Pediatricians.” [In eng]. Public Health Rep 126 Suppl 2 (Jul-Aug 2011): 13-23.

Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases.

Hviid, A., H. Svanstrom, N. M. Scheller, O. Gronlund, B. Pasternak, and L. Arnheim-Dahlstrom. “Human Papillomavirus Vaccination of Adult Women and Risk of Autoimmune and Neurological Diseases.” [In eng]. J Intern Med 283, no. 2 (Feb 2018): 154-65.

Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase.

Chandler, R. E., K. Juhlin, J. Fransson, O. Caster, I. R. Edwards, and G. N. Noren. “Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in Vigibase((R)).” [In eng]. Drug Saf 40, no. 1 (Jan 2017): 81-90.

Parental vaccine safety concerns in 2009.

Freed, G. L., S. J. Clark, A. T. Butchart, D. C. Singer, and M. M. Davis. “Parental Vaccine Safety Concerns in 2009.” [In eng]. Pediatrics 125, no. 4 (Apr 2010): 654-9.

Are parental vaccine safety concerns associated with receipt of measles-mumps-rubella, diphtheria and tetanus toxoids with acellular pertussis, or hepatitis B vaccines by children?

Bardenheier, B., H. Yusuf, B. Schwartz, D. Gust, L. Barker, and L. Rodewald. “Are Parental Vaccine Safety Concerns Associated with Receipt of Measles-Mumps-Rubella, Diphtheria and Tetanus Toxoids with Acellular Pertussis, or Hepatitis B Vaccines by Children?” [In eng]. Arch Pediatr Adolesc Med 158, no. 6 (Jun 2004): 569-75.

Parental perspectives of vaccine safety and experience of adverse events following immunisation.

Parrella, A., M. Gold, H. Marshall, A. Braunack-Mayer, and P. Baghurst. “Parental Perspectives of Vaccine Safety and Experience of Adverse Events Following Immunisation.” [In eng]. Vaccine 31, no. 16 (Apr 12 2013): 2067-74.

Acceptance of human papillomavirus vaccine by gynecologists in an urban setting.

Jaspan, D. M., C. J. Dunton, and T. L. Cook. “Acceptance of Human Papillomavirus Vaccine by Gynecologists in an Urban Setting.” [In eng]. J Low Genit Tract Dis 12, no. 2 (Apr 2008): 118-21.

Parental vaccine safety concerns: results from the National Immunization Survey, 2001-2002.

Allred, N. J., K. M. Shaw, T. A. Santibanez, D. L. Rickert, and J. M. Santoli. “Parental Vaccine Safety Concerns: Results from the National Immunization Survey, 2001-2002.” [In eng]. Am J Prev Med 28, no. 2 (Feb 2005): 221-4.

Missing the Target for Routine Human Papillomavirus Vaccination: Consistent and Strong Physician Recommendations Are Lacking for 11-to 12-Year-Old Males.

Vadaparampil, S. T., T. L. Malo, S. K. Sutton, K. N. Ali, J. A. Kahn, A. Casler, D. Salmon, et al. “Missing the Target for Routine Human Papillomavirus Vaccination: Consistent and Strong Physician Recommendations Are Lacking for 11- to 12-Year-Old Males.” [In eng]. Cancer Epidemiol Biomarkers Prev 25, no. 10 (Oct 2016): 1435-46.

Invited Commentary: Moving From Evidence to Impact for Human Papillomavirus Vaccination-The Critical Role of Translation and Communication in Epidemiology.

Rositch, A. F., and M. Krakow. “Invited Commentary: Moving from Evidence to Impact for Human Papillomavirus Vaccination-the Critical Role of Translation and Communication in Epidemiology.” [In eng]. Am J Epidemiol 187, no. 6 (Jun 1 2018): 1277-80.

Influenza vaccination in the 2009-2010 pandemic season: The experience of primary care physicians.

O’Leary, S. T., S. Stokley, L. A. Crane, M. A. Allison, L. P. Hurley, P. Wortley, C. I. Babbel, et al. “Influenza Vaccination in the 2009-2010 Pandemic Season: The Experience of Primary Care Physicians.” [In eng]. Prev Med 55, no. 1 (Jul 2012): 68-71.

Childhood vaccine finance and safety issues.

Giffin, R., K. Stratton, and R. Chalk. “Childhood Vaccine Finance and Safety Issues.” [In eng]. Health Aff (Millwood) 23, no. 5 (Sep-Oct 2004): 98-111.

The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations.

Karafillakis, E., and H. J. Larson. “The Benefit of the Doubt or Doubts over Benefits? A Systematic Literature Review of Perceived Risks of Vaccines in European Populations.” [In eng]. Vaccine 35, no. 37 (Sep 5 2017): 4840-50.

Molecular mimicry, inflammatory bowel disease, and the vaccine safety debate.

Yusung, S., and J. Braun. “Molecular Mimicry, Inflammatory Bowel Disease, and the Vaccine Safety Debate.” [In eng]. BMC Med 12 (Sep 18 2014): 166.

Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination.

Parretta, E., B. Ianniello, F. Ferrazin, F. Rossi, and A. Capuano. “Italian Post-Marketing Surveillance for Adverse Event Reports after Mf59-Adjuvanted H1n1v Vaccination.” [In eng]. Vaccine 29, no. 20 (May 9 2011): 3708-13.

Impact of unfounded vaccine safety concerns on the nationwide measles-rubella immunization campaign, Georgia, 2008.

Khetsuriani, N., P. Imnadze, L. Baidoshvili, L. Jabidze, N. Tatishili, G. Kurtsikashvili, T. Lezhava, E. Laurent, and R. Martin. “Impact of Unfounded Vaccine Safety Concerns on the Nationwide Measles-Rubella Immunization Campaign, Georgia, 2008.” [In eng]. Vaccine 28, no. 39 (Sep 7 2010): 6455-62.

Parental vaccine refusal in Wisconsin: a case-control study.

Salmon, D. A., M. J. Sotir, W. K. Pan, J. L. Berg, S. B. Omer, S. Stokley, D. J. Hopfensperger, J. P. Davis, and N. A. Halsey. “Parental Vaccine Refusal in Wisconsin: A Case-Control Study.” [In eng]. WMJ 108, no. 1 (Feb 2009): 17-23.

Global advisory committee on vaccine safety, 2-3 December 2015.

Global Advisory Committee on Vaccine Safety, 2-3 December 2015. [In eng fre]. Wkly Epidemiol Rec 91, no. 3 (Jan 22 2016): 21-31.

Immunisation safety: a priority of the World Health Organization’s Department of Vaccines and Biologicals.

Duclos, P., and C. A. Hofmann. “Immunisation Safety: A Priority of the World Health Organization’s Department of Vaccines and Biologicals.” [In eng]. Drug Saf 24, no. 15 (2001): 1105-12.

The Vaccine Safety Datalink: Immunization research in health maintenance organizations in the USA.

Chen, R. T., F. DeStefano, R. L. Davis, L. A. Jackson, R. S. Thompson, J. P. Mullooly, S. B. Black, et al. “The Vaccine Safety Datalink: Immunization Research in Health Maintenance Organizations in the USA.” [In eng]. Bull World Health Organ 78, no. 2 (2000): 186-94.

Supply and safety issues surrounding an H1N1 vaccine.

Supply and Safety Issues Surrounding an H1n1 Vaccine. [In eng]. Lancet 374, no. 9687 (Aug 1 2009): 358.

Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS.

Global Safety of Vaccines: Strengthening Systems for Monitoring, Management and the Role of Gacvs. [In eng]. Expert Rev Vaccines 8, no. 6 (Jun 2009): 705-16.

Safety of seasonal influenza and influenza A (H1N1) 2009 monovalent vaccines in pregnancy.

Moro, P. L., N. K. Tepper, L. A. Grohskopf, C. Vellozzi, and K. Broder. “Safety of Seasonal Influenza and Influenza a (H1n1) 2009 Monovalent Vaccines in Pregnancy.” [In eng]. Expert Rev Vaccines 11, no. 8 (Aug 2012): 911-21.

Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 1990-2016.

Moro, P. L., Y. Zheteyeva, F. Barash, P. Lewis, and M. Cano. “Assessing the Safety of Hepatitis B Vaccination During Pregnancy in the Vaccine Adverse Event Reporting System (Vaers), 1990-2016.” [In eng]. Vaccine 36, no. 1 (Jan 2 2018): 50-54.

FDA Safety Reviews on Drugs, Biologics, and Vaccines: 2007-2013.

Cope, J. U., G. L. Rosenthal, P. Weinel, A. Odegaard, and D. M. Murphy. “Fda Safety Reviews on Drugs, Biologics, and Vaccines: 2007-2013.” [In eng]. Pediatrics 136, no. 6 (Dec 2015): 1125-31.

Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents.

Saez-Llorens, X., D. C. Aguilera Vaca, K. Abarca, E. Maho, L. Han, I. Smolenov, and P. Dull. “Persistence of Meningococcal Antibodies and Response to a Third Dose after a Two-Dose Vaccination Series with Investigational Menabcwy Vaccine Formulations in Adolescents.” [In eng]. Pediatr Infect Dis J 34, no. 10 (Oct 2015): e264-78.

On the relationship between human papilloma virus vaccine and autoimmune diseases.

On the relationship between human papilloma virus vaccine and autoimmune diseases.

Monitoring vaccine safety during an influenza pandemic.

Iskander, J., P. Haber, and G. Herrera. “Monitoring Vaccine Safety During an Influenza Pandemic.” [In eng]. Yale J Biol Med 78, no. 5 (Oct 2005): 265-75.

Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers.

Klein, N. P., J. Shepard, L. Bedell, T. Odrljin, and P. Dull. “Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Measles, Mumps, Rubella, Varicella Vaccine in Healthy Toddlers.” [In eng]. Vaccine 30, no. 26 (Jun 6 2012): 3929-36.

Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy.

Beeler, J. A., and M. C. Eichelberger. “Influenza and Respiratory Syncytial Virus (Rsv) Vaccines for Infants: Safety, Immunogenicity, and Efficacy.” [In eng]. Microb Pathog 55 (Feb 2013): 9-15.

Safety of Quadrivalent Human Papillomavirus Vaccine Administered Routinely to Females.

Klein, N. P., J. Hansen, C. Chao, C. Velicer, M. Emery, J. Slezak, N. Lewis, et al. “Safety of Quadrivalent Human Papillomavirus Vaccine Administered Routinely to Females.” [In eng]. Arch Pediatr Adolesc Med 166, no. 12 (Dec 2012): 1140-8.

Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.

Arana, J. E., T. Harrington, M. Cano, P. Lewis, A. Mba-Jonas, L. Rongxia, B. Stewart, L. E. Markowitz, and T. T. Shimabukuro. “Post-Licensure Safety Monitoring of Quadrivalent Human Papillomavirus Vaccine in the Vaccine Adverse Event Reporting System (Vaers), 2009-2015.” [In eng]. Vaccine 36, no. 13 (Mar 20 2018): 1781-88.

Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.

Miller, E. R., P. L. Moro, M. Cano, P. Lewis, M. Bryant-Genevier, and T. T. Shimabukuro. “Post-Licensure Safety Surveillance of 23-Valent Pneumococcal Polysaccharide Vaccine in the Vaccine Adverse Event Reporting System (Vaers), 1990-2013.” [In eng]. Vaccine 34, no. 25 (May 27 2016): 2841-6.

Immunogenicity, Safety, and Immune Persistence of a Novel Inactivated Human Enterovirus 71 Vaccine: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.

Li, Y. P., Z. L. Liang, J. L. Xia, J. Y. Wu, L. Wang, L. F. Song, Q. Y. Mao, et al. “Immunogenicity, Safety, and Immune Persistence of a Novel Inactivated Human Enterovirus 71 Vaccine: A Phase Ii, Randomized, Double-Blind, Placebo-Controlled Trial.” [In eng]. J Infect Dis 209, no. 1 (Jan 1 2014): 46-55.

Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib vaccine in Canadian Aboriginal and non-Aboriginal infants.

Scheifele, D. W., M. Ferguson, G. Predy, M. Dawar, D. Assudani, S. Kuriyakose, O. Van Der Meeren, and H. H. Han. “Immunogenicity and Safety of 3-Dose Primary Vaccination with Combined Dtpa-Hbv-Ipv/Hib Vaccine in Canadian Aboriginal and Non-Aboriginal Infants.” [In eng]. Vaccine 33, no. 16 (Apr 15 2015): 1897-900.

Factors influencing uptake of influenza A (H1N1) vaccine amongst healthcare workers in a regional pediatric centre: Lessons for improving vaccination rates.

Chen, S. C., G. Hawkins, E. Aspinall, and N. Patel. “Factors Influencing Uptake of Influenza a (H1n1) Vaccine Amongst Healthcare Workers in a Regional Pediatric Centre: Lessons for Improving Vaccination Rates.” [In eng]. Vaccine 30, no. 2 (Jan 5 2012): 493-7.

Experience with the clinical development of influenza vaccines for potential pandemics.

Wood, J. M., K. G. Nicholson, I. Stephenson, M. Zambon, R. W. Newman, D. L. Major, and A. Podda. “Experience with the Clinical Development of Influenza Vaccines for Potential Pandemics.” [In eng]. Med Microbiol Immunol 191, no. 3-4 (Dec 2002): 197-201.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in >= 60-year-old adults.

Song, J. Y., H. J. Cheong, H. J. Hyun, Y. B. Seo, J. Lee, S. H. Wie, M. J. Choi, et al. “Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine and an Mf59-Adjuvanted Influenza Vaccine after Concomitant Vaccination in 60-Year-Old Adults.” [In eng]. Vaccine 35, no. 2 (Jan 5 2017): 313-20.

Incentives and disincentives to participate in prophylactic HIV vaccine research.

Jenkins, R. A., L. R. Temoshok, and K. Virochsiri. “Incentives and Disincentives to Participate in Prophylactic Hiv Vaccine Research.” [In eng]. J Acquir Immune Defic Syndr Hum Retrovirol 9, no. 1 (May 1 1995): 36-42.

Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial.

Hayton, E. J., A. Rose, U. Ibrahimsa, M. Del Sorbo, S. Capone, A. Crook, A. P. Black, L. Dorrell, and T. Hanke. “Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial.” [In eng]. PLoS One 9, no. 7 (2014): e101591.

Pandemic influenza A (H1N1) 2009 in a critical care and theatre setting: beliefs and attitudes towards staff vaccination.

Parry, H. M., S. Damery, A. Fergusson, H. Draper, J. Bion, and A. E. Low. “Pandemic Influenza a (H1n1) 2009 in a Critical Care and Theatre Setting: Beliefs and Attitudes Towards Staff Vaccination.” [In eng]. J Hosp Infect 78, no. 4 (Aug 2011): 302-7.

Genetic Instability of Live, Attenuated Human Immunodeficiency Virus Type 1 Vaccine Strains.

Berkhout, B., K. Verhoef, J. L. van Wamel, and N. K. Back. “Genetic Instability of Live, Attenuated Human Immunodeficiency Virus Type 1 Vaccine Strains.” [In eng]. J Virol 73, no. 2 (Feb 1999): 1138-45.

Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults.

DiazGranados, C. A., A. J. Dunning, C. A. Robertson, H. K. Talbot, V. Landolfi, and D. P. Greenberg. “Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults.” [In eng]. Clin Infect Dis 62, no. 9 (May 1 2016): 1092-99.

Preclinical and clinical safety studies on DNA vaccines.

Schalk, J. A., F. R. Mooi, G. A. Berbers, L. A. van Aerts, H. Ovelgonne, and T. G. Kimman. “Preclinical and Clinical Safety Studies on DNA Vaccines.” [In eng]. Hum Vaccin 2, no. 2 (Mar-Apr 2006): 45-53.

Omission bias and vaccine rejection by parents of healthy children: implications for the influenza A/H1N1 vaccination programme.

Brown, K. F., J. S. Kroll, M. J. Hudson, M. Ramsay, J. Green, C. A. Vincent, G. Fraser, and N. Sevdalis. “Omission Bias and Vaccine Rejection by Parents of Healthy Children: Implications for the Influenza a/H1n1 Vaccination Programme.” [In eng]. Vaccine 28, no. 25 (Jun 7 2010): 4181-5.

Cumulative and episodic vaccine aluminum exposure in a population-based cohort of young children.

Glanz, J. M., S. R. Newcomer, M. F. Daley, D. L. McClure, R. P. Baxter, M. L. Jackson, A. L. Naleway, M. M. Lugg, and F. DeStefano. “Cumulative and Episodic Vaccine Aluminum Exposure in a Population-Based Cohort of Young Children.” [In eng]. Vaccine 33, no. 48 (Nov 27 2015): 6736-44.

Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years.

Lalwani, S., S. Agarkhedkar, N. Gogtay, S. Palkar, U. Thatte, H. Vakil, R. Jonnalagedda, et al. “Safety and Immunogenicity of an Investigational Meningococcal Acwy Conjugate Vaccine (Menacwy-Crm) in Healthy Indian Subjects Aged 2 to 75 Years.” [In eng]. Int J Infect Dis 38 (Sep 2015): 36-42.

Pre-Vaccination Care-Seeking in Females Reporting Severe Adverse Reactions to HPV Vaccine. A Registry Based Case-Control Study.

Molbak, K., N. D. Hansen, and P. Valentiner-Branth. “Pre-Vaccination Care-Seeking in Females Reporting Severe Adverse Reactions to Hpv Vaccine. A Registry Based Case-Control Study.” [In eng]. PLoS One 11, no. 9 (2016): e0162520.

Genetically identical primate modelling systems for HIV vaccines.

Kent, S. J., and I. M. Lewis. “Genetically Identical Primate Modelling Systems for Hiv Vaccines.” [In eng]. Reprod Fertil Dev 10, no. 7-8 (1998): 651-7.

Examination of the safety of pediatric vaccine schedules in a non-human primate model: assessments of neurodevelopment, learning, and social behavior.

Curtis, B., N. Liberato, M. Rulien, K. Morrisroe, C. Kenney, V. Yutuc, C. Ferrier, et al. “Examination of the Safety of Pediatric Vaccine Schedules in a Non-Human Primate Model: Assessments of Neurodevelopment, Learning, and Social Behavior.” [In eng]. Environ Health Perspect 123, no. 6 (Jun 2015): 579-89.

A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine.

Vesikari, T., A. Karvonen, T. Korhonen, K. Edelman, R. Vainionpaa, A. Salmi, M. K. Saville, et al. “A Randomized, Double-Blind Study of the Safety, Transmissibility and Phenotypic and Genotypic Stability of Cold-Adapted Influenza Virus Vaccine.” [In eng]. Pediatr Infect Dis J 25, no. 7 (Jul 2006): 590-5.

Current status and future prospects for human papillomavirus vaccines.

Kim, H. J. “Current Status and Future Prospects for Human Papillomavirus Vaccines.” [In eng]. Arch Pharm Res 40, no. 9 (Sep 2017): 1050-63.

Plague vaccines and the molecular basis of immunity against Yersinia pestis.

Quenee, L. E., and O. Schneewind. “Plague Vaccines and the Molecular Basis of Immunity against Yersinia Pestis.” [In eng]. Hum Vaccin 5, no. 12 (Dec 2009): 817-23.

Novel vaccine strategies against emerging viruses.

Garcia-Sastre, A., and I. Mena. “Novel Vaccine Strategies against Emerging Viruses.” [In eng]. Curr Opin Virol 3, no. 2 (Apr 2013): 210-6.

Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines.

Black, S., J. Eskola, C. A. Siegrist, N. Halsey, N. MacDonald, B. Law, E. Miller, et al. “Importance of Background Rates of Disease in Assessment of Vaccine Safety During Mass Immunisation with Pandemic H1n1 Influenza Vaccines.” [In eng]. Lancet 374, no. 9707 (Dec 19 2009): 2115-22.

Delivering influenza vaccine to pregnant women.

Naleway, A. L., W. J. Smith, and J. P. Mullooly. “Delivering Influenza Vaccine to Pregnant Women.” [In eng]. Epidemiol Rev 28 (2006): 47-53.

Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.

Hopkins, R. J., G. Kalsi, V. M. Montalvo-Lugo, M. Sharma, Y. Wu, D. D. Muse, E. A. Sheldon, F. C. Hampel, and L. Lemiale. “Randomized, Double-Blind, Active-Controlled Study Evaluating the Safety and Immunogenicity of Three Vaccination Schedules and Two Dose Levels of Av7909 Vaccine for Anthrax Post-Exposure Prophylaxis in Healthy Adults.” [In eng]. Vaccine 34, no. 18 (Apr 19 2016): 2096-105.

Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali.

Vannice, K. S., M. Keita, S. O. Sow, A. P. Durbin, S. B. Omer, L. H. Moulton, T. M. Yameogo, et al. “Active Surveillance for Adverse Events after a Mass Vaccination Campaign with a Group a Meningococcal Conjugate Vaccine (Psa-Tt) in Mali.” [In eng]. Clin Infect Dis 61 Suppl 5 (Nov 15 2015): S493-500.

The next decade of vaccines: societal and scientific challenges.

Moxon, E. R., and C. A. Siegrist. “The Next Decade of Vaccines: Societal and Scientific Challenges.” [In eng]. Lancet 378, no. 9788 (Jul 23 2011): 348-59.

The Vaccine Safety Datalink project.

DeStefano, F. “The Vaccine Safety Datalink Project.” [In eng]. Pharmacoepidemiol Drug Saf 10, no. 5 (Aug-Sep 2001): 403-6.

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.

Schwarz, T. F., N. Aggarwal, B. Moeckesch, I. Schenkenberger, C. Claeys, M. Douha, O. Godeaux, et al. “Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered with Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.” [In eng]. J Infect Dis 216, no. 11 (Dec 12 2017): 1352-61.

Assessing the safety of influenza immunization during pregnancy: the Vaccine Safety Datalink.

Kharbanda, E. O., G. Vazquez-Benitez, W. X. Shi, H. Lipkind, A. Naleway, B. Molitor, L. Kuckler, A. Olsen, and J. D. Nordin. “Assessing the Safety of Influenza Immunization During Pregnancy: The Vaccine Safety Datalink.” [In eng]. Am J Obstet Gynecol 207, no. 3 Suppl (Sep 2012): S47-51.

Vaccine update 2009: questions around the safety of the influenza A (H1N1) vaccine.

Siegrist, C. A. “[Vaccine Update 2009: Questions around the Safety of the Influenza a (H1n1) Vaccine].” [In fre]. Rev Med Suisse 6, no. 231 (Jan 13 2010): 67-70.

Vaccine Case-Population: A New Method for Vaccine Safety Surveillance.

Theophile, H., N. Moore, P. Robinson, B. Begaud, and A. Pariente. “Vaccine Case-Population: A New Method for Vaccine Safety Surveillance.” [In eng]. Drug Saf 39, no. 12 (Dec 2016): 1197-209.

Acceptance of and attitudes towards human papillomavirus vaccination in Japanese mothers of adolescent girls.

Hanley, S. J., E. Yoshioka, Y. Ito, R. Konno, Y. Hayashi, R. Kishi, and N. Sakuragi. “Acceptance of and Attitudes Towards Human Papillomavirus Vaccination in Japanese Mothers of Adolescent Girls.” [In eng]. Vaccine 30, no. 39 (Aug 24 2012): 5740-7.

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine Final analysis of a long-term follow-up study up to 9.4 years post-vaccination.

Naud, P. S., C. M. Roteli-Martins, N. S. De Carvalho, J. C. Teixeira, P. C. de Borba, N. Sanchez, T. Zahaf, et al. “Sustained Efficacy, Immunogenicity, and Safety of the Hpv-16/18 As04-Adjuvanted Vaccine: Final Analysis of a Long-Term Follow-up Study up to 9.4 Years Post-Vaccination.” [In eng]. Hum Vaccin Immunother 10, no. 8 (2014): 2147-62.

Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.

Sukumaran, L., M. M. McNeil, P. L. Moro, P. W. Lewis, S. K. Winiecki, and T. T. Shimabukuro. “Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (Vaers), 2003-2013.” [In eng]. Clin Infect Dis 60, no. 10 (May 15 2015): e58-65.

Postlicensure Safety Surveillance for High-Dose Trivalent Inactivated Influenza Vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010.

Moro, P. L., J. Arana, M. Cano, D. Menschik, X. Yue, P. Lewis, P. Haber, D. Martin, and K. Broder. “Postlicensure Safety Surveillance for High-Dose Trivalent Inactivated Influenza Vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010.” [In eng]. Clin Infect Dis 54, no. 11 (Jun 2012): 1608-14.

Pandemic 2009 influenza H1N1 virus vaccination: compliance and safety in a single hemodialysis center.

Stavroulopoulos, A., G. Stamogiannos, and V. Aresti. “Pandemic 2009 Influenza H1n1 Virus Vaccination: Compliance and Safety in a Single Hemodialysis Center.” [In eng]. Ren Fail 32, no. 9 (2010): 1044-8.

Vaccine shot-limiting: Estimating the prevalence, indicators, and impact on vaccination status – Michigan, 2012.

Weinberg, M., S. Dietz, R. Potter, R. Swanson, C. Miller, and J. McFadden. “Vaccine Shot-Limiting: Estimating the Prevalence, Indicators, and Impact on Vaccination Status – Michigan, 2012.” [In eng]. Vaccine 35, no. 7 (Feb 15 2017): 1018-23.

Parental vaccine concerns in Kentucky.

Smith, M. J., C. R. Woods, and G. S. Marshall. “Parental Vaccine Concerns in Kentucky.” [In eng]. J Ky Med Assoc 107, no. 9 (Sep 2009): 342-9.

Global advisory committee on vaccine safety, 30 November – 1 December 2016.

Global Advisory Committee on Vaccine Safety, 30 November – 1 December 2016. [In eng fre]. Wkly Epidemiol Rec 92, no. 2 (Jan 13 2017): 13-20.

A comprehensive analysis of Italian web pages mentioning squalene-based influenza vaccine adjuvants reveals a high prevalence of misinformation.

Panatto, D., D. Amicizia, L. Arata, P. L. Lai, and R. Gasparini. “A Comprehensive Analysis of Italian Web Pages Mentioning Squalene-Based Influenza Vaccine Adjuvants Reveals a High Prevalence of Misinformation.” [In eng]. Hum Vaccin Immunother 14, no. 4 (Apr 3 2018): 969-77.

The future of human DNA vaccines.

Li, L., F. Saade, and N. Petrovsky. “The Future of Human DNA Vaccines.” [In eng]. J Biotechnol 162, no. 2-3 (Dec 31 2012): 171-82.

PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4(+) T cell transcriptomal molecular signatures.

Hoft, D. F., M. Xia, G. L. Zhang, A. Blazevic, J. Tennant, C. Kaplan, G. Matuschak, et al. “Po and Id Bcg Vaccination in Humans Induce Distinct Mucosal and Systemic Immune Responses and Cd4(+) T Cell Transcriptomal Molecular Signatures.” [In eng]. Mucosal Immunol 11, no. 2 (Mar 2018): 486-95.

Human papillomavirus vaccine introduction–the first five years.

Markowitz, L. E., V. Tsu, S. L. Deeks, H. Cubie, S. A. Wang, A. S. Vicari, and J. M. Brotherton. “Human Papillomavirus Vaccine Introduction–the First Five Years.” [In eng]. Vaccine 30 Suppl 5 (Nov 20 2012): F139-48.

A global perspective on vaccine safety and public health: the Global Advisory Committee on Vaccine Safety.

Folb, P. I., E. Bernatowska, R. Chen, J. Clemens, A. N. Dodoo, S. S. Ellenberg, C. P. Farrington, et al. “A Global Perspective on Vaccine Safety and Public Health: The Global Advisory Committee on Vaccine Safety.” [In eng]. Am J Public Health 94, no. 11 (Nov 2004): 1926-31.

Vaccine components and constituents: responding to consumer concerns.

Eldred, B. E., A. J. Dean, T. M. McGuire, and A. L. Nash. “Vaccine Components and Constituents: Responding to Consumer Concerns.” [In eng]. Med J Aust 184, no. 4 (Feb 20 2006): 170-5.

Issues associated with residual cell-substrate DNA in viral vaccines.

Sheng-Fowler, L., A. M. Lewis, Jr., and K. Peden. “Issues Associated with Residual Cell-Substrate DNA in Viral Vaccines.” [In eng]. Biologicals 37, no. 3 (Jun 2009): 190-5.

Quick assessment of the influence of the Hepatitis B vaccine event on children’s vaccination.

Yue, C., X. Sun, N. Wei, W. Yu, F. Cui, H. Wang, L. Li, et al. “Quick Assessment of the Influence of the Hepatitis B Vaccine Event on Children’s Vaccination.” [In eng]. Hum Vaccin Immunother 12, no. 10 (Oct 2 2016): 2611-15.

Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.

Pomfret, T. C., J. M. Gagnon, Jr., and A. T. Gilchrist. “Quadrivalent Human Papillomavirus (Hpv) Vaccine: A Review of Safety, Efficacy, and Pharmacoeconomics.” [In eng]. J Clin Pharm Ther 36, no. 1 (Feb 2011): 1-9.

The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper.

Halsey, N. A., K. R. Talaat, A. Greenbaum, E. Mensah, M. Z. Dudley, T. Proveaux, and D. A. Salmon. “The Safety of Influenza Vaccines in Children: An Institute for Vaccine Safety White Paper.” [In eng]. Vaccine 33 Suppl 5 (Dec 30 2015): F1-F67.

DNA vaccines: safety and efficacy issues.

Klinman, D. M., M. Takeno, M. Ichino, M. Gu, G. Yamshchikov, G. Mor, and J. Conover. “DNA Vaccines: Safety and Efficacy Issues.” [In eng]. Springer Semin Immunopathol 19, no. 2 (1997): 245-56.

Vaccine safety controversies and the future of vaccination programs.

Francois, G., P. Duclos, H. Margolis, D. Lavanchy, C. A. Siegrist, A. Meheus, P. H. Lambert, et al. “Vaccine Safety Controversies and the Future of Vaccination Programs.” [In eng]. Pediatr Infect Dis J 24, no. 11 (Nov 2005): 953-61.

Progress in Development of Group A Streptococcus Vaccines.

Song, Y., X. Zhang, C. Lu, F. Zhang, and H. Zhu. “Progress in Development of Group a Streptococcus Vaccines.” [In eng]. Curr Pharm Biotechnol 14, no. 11 (2013): 947-50.

The vaccine data link in Nha Trang, Vietnam: a progress report on the implementation of a database to detect adverse events related to vaccinations.

Ali, M., D. G. Canh, J. D. Clemens, J. K. Park, L. von Seidlein, V. D. Thiem, H. Tho le, and D. D. Trach. “The Vaccine Data Link in Nha Trang, Vietnam: A Progress Report on the Implementation of a Database to Detect Adverse Events Related to Vaccinations.” [In eng]. Vaccine 21, no. 15 (Apr 2 2003): 1681-6.

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.

Grupping, K., L. Campora, M. Douha, T. C. Heineman, N. P. Klein, H. Lal, J. Peterson, I. Vastiau, and L. Oostvogels. “Immunogenicity and Safety of the Hz/Su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated with a Live Attenuated Herpes Zoster Vaccine.” [In eng]. J Infect Dis 216, no. 11 (Dec 12 2017): 1343-51.

Vaccine-Acquired Rotavirus in Infants with Severe Combined Immunodeficiency.

Patel, N. C., P. M. Hertel, M. K. Estes, M. de la Morena, A. M. Petru, L. M. Noroski, P. A. Revell, et al. “Vaccine-Acquired Rotavirus in Infants with Severe Combined Immunodeficiency.” [In eng]. N Engl J Med 362, no. 4 (Jan 28 2010): 314-9.

Acceptability and Feasibility of Delivering Pentavalent Vaccines in a Compact, Prefilled, Autodisable Device in Vietnam and Senegal.

Guillermet, E., H. M. Dicko, T. P. Mai le, M. N’Diaye, F. Hane, S. O. Ba, K. Gomis, et al. “Acceptability and Feasibility of Delivering Pentavalent Vaccines in a Compact, Prefilled, Autodisable Device in Vietnam and Senegal.” [In eng]. PLoS One 10, no. 7 (2015): e0132292.

Infant outcomes after exposure to Tdap vaccine in pregnancy: an observational study.

Walls, T., P. Graham, H. Petousis-Harris, L. Hill, and N. Austin. “Infant Outcomes after Exposure to Tdap Vaccine in Pregnancy: An Observational Study.” [In eng]. BMJ Open 6, no. 1 (Jan 6 2016): e009536.

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Chen, R. T., B. Carbery, L. Mac, K. I. Berns, L. Chapman, R. C. Condit, J. L. Excler, et al. “The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3swg).” [In eng]. Vaccine 33, no. 1 (Jan 1 2015): 73-5.

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring.

Vellozzi, C., D. R. Burwen, A. Dobardzic, R. Ball, K. Walton, and P. Haber. “Safety of Trivalent Inactivated Influenza Vaccines in Adults: Background for Pandemic Influenza Vaccine Safety Monitoring.” [In eng]. Vaccine 27, no. 15 (Mar 26 2009): 2114-20.

Influenza vaccination and fetal and neonatal outcomes.

Fell, D. B., L. Dodds, N. E. MacDonald, V. M. Allen, and S. McNeil. “Influenza Vaccination and Fetal and Neonatal Outcomes.” [In eng]. Expert Rev Vaccines 12, no. 12 (Dec 2013): 1417-30.

Trends in reasons for non-receipt of influenza vaccination during pregnancy in Georgia, 2004-2011.

Chamberlain, A. T., R. L. Berkelman, K. A. Ault, E. S. Rosenberg, W. A. Orenstein, and S. B. Omer. “Trends in Reasons for Non-Receipt of Influenza Vaccination During Pregnancy in Georgia, 2004-2011.” [In eng]. Vaccine 34, no. 13 (Mar 18 2016): 1597-603.

Monitoring vaccine safety during measles mass immunization campaigns: Clinical and programmatic issues.

Pless, R. P., A. D. Bentsi-Enchill, and P. Duclos. “Monitoring Vaccine Safety During Measles Mass Immunization Campaigns: Clinical and Programmatic Issues.” [In eng]. J Infect Dis 187 Suppl 1 (May 15 2003): S291-8.

Successful methodology for large-scale surveillance of severe events following influenza vaccination in Canada, 2011 and 2012.

Bettinger, J. A., I. Rouleau, M. C. Gariepy, W. R. Bowie, L. Valiquette, O. G. Vanderkooi, J. D. Kellner, et al. “Successful Methodology for Large-Scale Surveillance of Severe Events Following Influenza Vaccination in Canada, 2011 and 2012.” [In eng]. Euro Surveill 20, no. 29 (Jul 23 2015): 21189.

Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population.

Sukumaran, L., N. L. McCarthy, R. Li, E. S. Weintraub, S. J. Jacobsen, S. J. Hambidge, L. A. Jackson, et al. “Demographic Characteristics of Members of the Vaccine Safety Datalink (Vsd): A Comparison with the United States Population.” [In eng]. Vaccine 33, no. 36 (Aug 26 2015): 4446-50.

Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System.

Arana, J., A. Mba-Jonas, C. Jankosky, P. Lewis, P. L. Moro, T. T. Shimabukuro, and M. Cano. “Reports of Postural Orthostatic Tachycardia Syndrome after Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System.” [In eng]. J Adolesc Health 61, no. 5 (Nov 2017): 577-82.

Pediatricians’ intention to recommend human papillomavirus (HPV) vaccines to 11- to 12-year-old girls postlicensing.

Feemster, K. A., S. E. Winters, A. G. Fiks, S. Kinsman, and J. A. Kahn. “Pediatricians’ Intention to Recommend Human Papillomavirus (Hpv) Vaccines to 11- to 12-Year-Old Girls Postlicensing.” [In eng]. J Adolesc Health 43, no. 4 (Oct 2008): 408-11.

First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.

Choi, E., C. J. Michalski, S. H. Choo, G. N. Kim, E. Banasikowska, S. Lee, K. Wu, et al. “First Phase I Human Clinical Trial of a Killed Whole-Hiv-1 Vaccine: Demonstration of Its Safety and Enhancement of Anti-Hiv Antibody Responses.” [In eng]. Retrovirology 13, no. 1 (Nov 28 2016): 82.

Status and challenges of filovirus vaccines.

Reed, D. S., and M. Mohamadzadeh. “Status and Challenges of Filovirus Vaccines.” [In eng]. Vaccine 25, no. 11 (Mar 1 2007): 1923-34.

Beliefs, behaviors and HPV vaccine: Correcting the myths and the misinformation.

Zimet, G. D., Z. Rosberger, W. A. Fisher, S. Perez, and N. W. Stupiansky. “Beliefs, Behaviors and Hpv Vaccine: Correcting the Myths and the Misinformation.” [In eng]. Prev Med 57, no. 5 (Nov 2013): 414-8.

A blueprint for DNA vaccine design.

Iurescia, S., D. Fioretti, and M. Rinaldi. “A Blueprint for DNA Vaccine Design.” [In eng]. Methods Mol Biol 1143 (2014): 3-10.

Postmarketing Evaluation of the Short-term Safety of the Pentavalent Rotavirus Vaccine.

Loughlin, J., T. C. Mast, M. C. Doherty, F. T. Wang, J. Wong, and J. D. Seeger. “Postmarketing Evaluation of the Short-Term Safety of the Pentavalent Rotavirus Vaccine.” [In eng]. Pediatr Infect Dis J 31, no. 3 (Mar 2012): 292-6.

Factors associated with uptake of vaccination against pandemic influenza: a systematic review.

Bish, A., L. Yardley, A. Nicoll, and S. Michie. “Factors Associated with Uptake of Vaccination against Pandemic Influenza: A Systematic Review.” [In eng]. Vaccine 29, no. 38 (Sep 2 2011): 6472-84.

Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo (R)) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.

Myers, T. R., M. M. McNeil, C. S. Ng, R. Li, P. W. Lewis, and M. V. Cano. “Adverse Events Following Quadrivalent Meningococcal Crm-Conjugate Vaccine (Menveo(R)) Reported to the Vaccine Adverse Event Reporting System (Vaers), 2010-2015.” [In eng]. Vaccine 35, no. 14 (Mar 27 2017): 1758-63.

Uptake of influenza vaccine in pregnant women during the 2009 H1N1 influenza pandemic.

Goldfarb, I., B. Panda, B. Wylie, and L. Riley. “Uptake of Influenza Vaccine in Pregnant Women During the 2009 H1n1 Influenza Pandemic.” [In eng]. Am J Obstet Gynecol 204, no. 6 Suppl 1 (Jun 2011): S112-5.

Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009.

Moro, P. L., K. Broder, Y. Zheteyeva, K. Walton, P. Rohan, A. Sutherland, A. Guh, et al. “Adverse Events in Pregnant Women Following Administration of Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine in the Vaccine Adverse Event Reporting System, 1990-2009.” [In eng]. Am J Obstet Gynecol 204, no. 2 (Feb 2011): 146 e1-7.

An update on human immunodeficiency virus vaccine preparedness studies.

Dhalla, S. “An Update on Human Immunodeficiency Virus Vaccine Preparedness Studies.” [In eng]. J Med Microbiol 64, no. 7 (Jul 2015): 731-8.

Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women.

Abzug, M. J., S. A. Nachman, P. Muresan, E. Handelsman, D. H. Watts, T. Fenton, B. Heckman, et al. “Safety and Immunogenicity of 2009 Ph1n1 Vaccination in Hiv-Infected Pregnant Women.” [In eng]. Clin Infect Dis 56, no. 10 (May 2013): 1488-97.

Zoonoses and fertility control in wildlife: Requirements for vaccines.

Stohr, K., and F. X. Meslin. “Zoonoses and Fertility Control in Wildlife–Requirements for Vaccines.” [In eng]. Reprod Fertil Dev 9, no. 1 (1997): 149-55.

Vaccine administration and the development of immune thrombocytopenic purpura in children.

Cecinati, V., N. Principi, L. Brescia, P. Giordano, and S. Esposito. “Vaccine Administration and the Development of Immune Thrombocytopenic Purpura in Children.” [In eng]. Hum Vaccin Immunother 9, no. 5 (May 2013): 1158-62.

Influenza vaccine: Delayed vaccination schedules and missed opportunities in children under 2 years old.

Gentile, A., M. Juarez, S. Hernandez, A. Moya, J. Bakir, and M. Lucion. “Influenza Vaccine: Delayed Vaccination Schedules and Missed Opportunities in Children under 2 Years Old.” [In eng]. Vaccine 33, no. 32 (Jul 31 2015): 3913-7.

Influenza vaccination of patients with systemic lupus erythematosus: safety and immunogenecity issues.

Abu-Shakra, M., J. Press, D. Buskila, and S. Sukenik. “Influenza Vaccination of Patients with Systemic Lupus Erythematosus: Safety and Immunogenecity Issues.” [In eng]. Autoimmun Rev 6, no. 8 (Sep 2007): 543-6.

Non-Human Primate Models for AIDS Vaccine Research.

Hu, S. L. “Non-Human Primate Models for Aids Vaccine Research.” [In eng]. Curr Drug Targets Infect Disord 5, no. 2 (Jun 2005): 193-201.

Post-licensure evaluation of vaccine safety: Current status and future directions. Symposium organised by the International Alliance for Biological Standardization (IABS) in Barcelona, Spain, 27-28 April 2011.

Black, S., W. Egan, and P. H. Lambert. “Post-Licensure Evaluation of Vaccine Safety: Current Status and Future Directions. Symposium Organised by the International Alliance for Biological Standardization (Iabs) in Barcelona, Spain, 27-28 April 2011.” [In eng]. Biologicals 40, no. 5 (Sep 2012): 382-3.

Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine.

Busse, W. W., S. P. Peters, M. J. Fenton, H. Mitchell, E. R. Bleecker, M. Castro, S. Wenzel, et al. “Vaccination of Patients with Mild and Severe Asthma with a 2009 Pandemic H1n1 Influenza Virus Vaccine.” [In eng]. J Allergy Clin Immunol 127, no. 1 (Jan 2011): 130-7, 37 e1-3.

Meeting of the Global Advisory Committee on Vaccine Safety, 7-8 June 2017.

Meeting of the Global Advisory Committee on Vaccine Safety, 7-8 June 2017. [In eng fre]. Wkly Epidemiol Rec 92, no. 28 (Jul 14 2017): 393-402.

Safety of influenza vaccination during pregnancy: A review of subsequent maternal obstetric events and findings from two recent cohort studies.

Naleway, A. L., S. A. Irving, M. L. Henninger, D. K. Li, P. Shifflett, S. Ball, J. L. Williams, et al. “Safety of Influenza Vaccination During Pregnancy: A Review of Subsequent Maternal Obstetric Events and Findings from Two Recent Cohort Studies.” [In eng]. Vaccine 32, no. 26 (May 30 2014): 3122-7.

From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Guy, B., B. Barrere, C. Malinowski, M. Saville, R. Teyssou, and J. Lang. “From Research to Phase Iii: Preclinical, Industrial and Clinical Development of the Sanofi Pasteur Tetravalent Dengue Vaccine.” [In eng]. Vaccine 29, no. 42 (Sep 23 2011): 7229-41.

Human metapneumovirus: Enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged.

Yim, K. C., R. P. Cragin, M. S. Boukhvalova, J. C. Blanco, M. E. Hamlin, G. Boivin, D. D. Porter, and G. A. Prince. “Human Metapneumovirus: Enhanced Pulmonary Disease in Cotton Rats Immunized with Formalin-Inactivated Virus Vaccine and Challenged.” [In eng]. Vaccine 25, no. 27 (Jun 28 2007): 5034-40.

HIV vaccines: New frontiers in vaccine development.

Duerr, A., J. N. Wasserheit, and L. Corey. “Hiv Vaccines: New Frontiers in Vaccine Development.” [In eng]. Clin Infect Dis 43, no. 4 (Aug 15 2006): 500-11.

Improving influenza vaccination coverage in pregnancy in Melbourne 2010-2011.

McCarthy, E. A., W. E. Pollock, T. Nolan, S. Hay, and S. McDonald. “Improving Influenza Vaccination Coverage in Pregnancy in Melbourne 2010-2011.” [In eng]. Aust N Z J Obstet Gynaecol 52, no. 4 (Aug 2012): 334-41.

Adverse events after Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010.

Moro, P. L., X. Yue, P. Lewis, P. Haber, and K. Broder. “Adverse Events after Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Administered to Adults 65 Years of Age and Older Reported to the Vaccine Adverse Event Reporting System (Vaers), 2005-2010.” [In eng]. Vaccine 29, no. 50 (Nov 21 2011): 9404-8.

Barriers and facilitators to influenza vaccination and vaccine coverage in a cohort of health care personnel.

Naleway, A. L., E. M. Henkle, S. Ball, S. Bozeman, M. J. Gaglani, E. D. Kennedy, and M. G. Thompson. “Barriers and Facilitators to Influenza Vaccination and Vaccine Coverage in a Cohort of Health Care Personnel.” [In eng]. Am J Infect Control 42, no. 4 (Apr 2014): 371-5.

Safety of combination vaccines: Perception versus reality.

Halsey, N. A. “Safety of Combination Vaccines: Perception Versus Reality.” [In eng]. Pediatr Infect Dis J 20, no. 11 Suppl (Nov 2001): S40-4.

Focusing on flu Parent perspectives on school-located immunization programs for influenza vaccine.

Middleman, A. B., M. B. Short, and J. S. Doak. “Focusing on Flu: Parent Perspectives on School-Located Immunization Programs for Influenza Vaccine.” [In eng]. Hum Vaccin Immunother 8, no. 10 (Oct 2012): 1395-400.

Public health worker attitudes and beliefs concerning 2009 H1N1 and seasonal influenza vaccines.

Walker, D. W., S. S. Sloan, and J. D. Kozlica. “Public Health Worker Attitudes and Beliefs Concerning 2009 H1n1 and Seasonal Influenza Vaccines.” [In eng]. Am J Infect Control 40, no. 3 (Apr 2012): 267-9.

Pandemic influenza A(H1N1) 2009 vaccines in the European Union.

Johansen, K., A. Nicoll, B. C. Ciancio, and P. Kramarz. “Pandemic Influenza a(H1n1) 2009 Vaccines in the European Union.” [In eng]. Euro Surveill 14, no. 41 (Oct 15 2009): 19361.

Campylobacter jejuni Strain CG8421: A Refined Model for the Study of Campylobacteriosis and Evaluation of Campylobacter Vaccines in Human Subjects.

Tribble, D. R., S. Baqar, M. P. Carmolli, C. Porter, K. K. Pierce, K. Sadigh, P. Guerry, et al. “Campylobacter Jejuni Strain Cg8421: A Refined Model for the Study of Campylobacteriosis and Evaluation of Campylobacter Vaccines in Human Subjects.” [In eng]. Clin Infect Dis 49, no. 10 (Nov 15 2009): 1512-9.

Strategic priorities for respiratory syncytial virus (RSV) vaccine development.

Anderson, L. J., P. R. Dormitzer, D. J. Nokes, R. Rappuoli, A. Roca, and B. S. Graham. “Strategic Priorities for Respiratory Syncytial Virus (Rsv) Vaccine Development.” [In eng]. Vaccine 31 Suppl 2 (Apr 18 2013): B209-15.

Emerging data on the safety and efficacy of influenza vaccines in children.

Vesikari, T. “Emerging Data on the Safety and Efficacy of Influenza Vaccines in Children.” [In eng]. Pediatr Infect Dis J 27, no. 11 Suppl (Nov 2008): S159-61.

Functional Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Pol or HIV-1 Gag- Pol and Env Expressed from a Single Rhabdovirus-Based Vaccine Vector Genome.

McGettigan, J. P., K. Naper, J. Orenstein, M. Koser, P. M. McKenna, and M. J. Schnell. “Functional Human Immunodeficiency Virus Type 1 (Hiv-1) Gag-Pol or Hiv-1 Gag-Pol and Env Expressed from a Single Rhabdovirus-Based Vaccine Vector Genome.” [In eng]. J Virol 77, no. 20 (Oct 2003): 10889-99.

Analysis of cell-mediated immune responses in support of dengue vaccine development efforts.

Rothman, A. L., J. R. Currier, H. L. Friberg, and A. Mathew. “Analysis of Cell-Mediated Immune Responses in Support of Dengue Vaccine Development Efforts.” [In eng]. Vaccine 33, no. 50 (Dec 10 2015): 7083-90.

Factors influencing laboratory workers’ decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC’s anthrax vaccination program.

Fowler, G. L., J. M. Baggs, E. S. Weintraub, S. W. Martin, M. M. McNeil, and D. A. Gust. “Factors Influencing Laboratory Workers’ Decisions to Accept or Decline Anthrax Vaccine Adsorbed (Ava): Results of a Decision-Making Study in Cdc’s Anthrax Vaccination Program.” [In eng]. Pharmacoepidemiol Drug Saf 15, no. 12 (Dec 2006): 880-8.

Death and serious illness following influenza vaccination: a multidisciplinary investigation.

Rue-Cover, A., J. Iskander, S. Lyn, D. R. Burwen, P. Gargiullo, S. Shadomy, J. Blostein, et al. “Death and Serious Illness Following Influenza Vaccination: A Multidisciplinary Investigation.” [In eng]. Pharmacoepidemiol Drug Saf 18, no. 6 (Jun 2009): 504-11.

Adverse Events following Haemophilus influenzae Type b Vaccines in the Vaccine Adverse Event Reporting System, 1990-2013.

Moro, P. L., C. Jankosky, D. Menschik, P. Lewis, J. Duffy, B. Stewart, and T. T. Shimabukuro. “Adverse Events Following Haemophilus Influenzae Type B Vaccines in the Vaccine Adverse Event Reporting System, 1990-2013.” [In eng]. J Pediatr 166, no. 4 (Apr 2015): 992-7.

Predictors of seasonal influenza vaccination during pregnancy.

Henninger, M., A. Naleway, B. Crane, J. Donahue, and S. Irving. “Predictors of Seasonal Influenza Vaccination During Pregnancy.” [In eng]. Obstet Gynecol 121, no. 4 (Apr 2013): 741-9.

Immunization-Safety Monitoring Systems for the 2009 H1N1 Monovalent Influenza Vaccination Program.

Salmon, D. A., A. Akhtar, M. J. Mergler, K. S. Vannice, H. Izurieta, R. Ball, G. M. Lee, et al. “Immunization-Safety Monitoring Systems for the 2009 H1n1 Monovalent Influenza Vaccination Program.” [In eng]. Pediatrics 127 Suppl 1 (May 2011): S78-86.

Knowledge, awareness and practices towards seasonal influenza and its vaccine: implications for future vaccination campaigns in Jordan.

Abu-Rish, E. Y., E. R. Elayeh, L. A. Mousa, Y. K. Butanji, and A. M. Albsoul-Younes. “Knowledge, Awareness and Practices Towards Seasonal Influenza and Its Vaccine: Implications for Future Vaccination Campaigns in Jordan.” [In eng]. Fam Pract 33, no. 6 (Dec 2016): 690-97.

Attitudes and side effects related to pandemic influenza A (H1N1) vaccination in healthcare personnel.

Ormen, B., N. Turker, I. Vardar, F. Kaptan, S. El, S. Ural, F. Kaya, and N. A. Coskun. “[Attitudes and Side Effects Related to Pandemic Influenza a (H1n1) Vaccination in Healthcare Personnel].” [In tur]. Mikrobiyol Bul 46, no. 1 (Jan 2012): 57-64.

Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults.

Macaladad, N., T. Marcano, M. Guzman, J. Moya, F. Jurado, M. Thompson, C. Meechan, et al. “Safety and Immunogenicity of a Zoster Vaccine in Varicella-Zoster Virus Seronegative and Low-Seropositive Healthy Adults.” [In eng]. Vaccine 25, no. 11 (Mar 1 2007): 2139-44.

A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years.

Nelson, E. A., H. S. Lam, K. C. Choi, W. C. Ho, L. W. Fung, F. W. Cheng, R. Y. Sung, M. Royals, and P. K. Chan. “A Pilot Randomized Study to Assess Immunogenicity, Reactogenicity, Safety and Tolerability of Two Human Papillomavirus Vaccines Administered Intramuscularly and Intradermally to Females Aged 18-26 Years.” [In eng]. Vaccine 31, no. 34 (Jul 25 2013): 3452-60.

Healthcare workers and influenza vaccination: an ERS-ESCMID Web-based survey.

Blasi, F., P. Palange, G. Rohde, T. Severin, G. Cornaglia, and R. Finch. “Healthcare Workers and Influenza Vaccination: An Ers-Escmid Web-Based Survey.” [In eng]. Clin Microbiol Infect 17, no. 8 (Aug 2011): 1223-5.

Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women.

Kojic, E. M., M. Kang, M. S. Cespedes, T. Umbleja, C. Godfrey, R. T. Allen, C. Firnhaber, et al. “Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Hiv-1-Infected Women.” [In eng]. Clin Infect Dis 59, no. 1 (Jul 1 2014): 127-35.

Intent to Receive Pandemic Influenza A (H1N1) Vaccine, Compliance with Social Distancing and Sources of Information in NC, 2009.

Horney, J. A., Z. Moore, M. Davis, and P. D. MacDonald. “Intent to Receive Pandemic Influenza a (H1n1) Vaccine, Compliance with Social Distancing and Sources of Information in Nc, 2009.” [In eng]. PLoS One 5, no. 6 (Jun 18 2010): e11226.

Healthcare worker compliance with seasonal and pandemic influenza vaccination.

Bellia, C., M. Setbon, P. Zylberman, and A. Flahault. “Healthcare Worker Compliance with Seasonal and Pandemic Influenza Vaccination.” [In eng]. Influenza Other Respir Viruses 7 Suppl 2 (Sep 2013): 97-104.

Attitudes, Knowledge and Factors Associated with Human Papillomavirus (HPV) Vaccine Uptake in Adolescent Girls and Young Women in Victoria, Australia.

Tung, I. L., D. A. Machalek, and S. M. Garland. “Attitudes, Knowledge and Factors Associated with Human Papillomavirus (Hpv) Vaccine Uptake in Adolescent Girls and Young Women in Victoria, Australia.” [In eng]. PLoS One 11, no. 8 (2016): e0161846.

Responses to A(H1N1)pdm09 Influenza Vaccines in Participants Previously Vaccinated With Seasonal Influenza Vaccine: A Randomized, Observer-Blind, Controlled Study.

Roy-Ghanta, S., R. Van der Most, P. Li, and D. W. Vaughn. “Responses to a(H1n1)Pdm09 Influenza Vaccines in Participants Previously Vaccinated with Seasonal Influenza Vaccine: A Randomized, Observer-Blind, Controlled Study.” [In eng]. J Infect Dis 210, no. 9 (Nov 1 2014): 1419-30.

Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.

Rosenberg, M., R. Sparks, A. McMahon, J. Iskander, J. D. Campbell, and K. M. Edwards. “Serious Adverse Events Rarely Reported after Trivalent Inactivated Influenza Vaccine (Tiv) in Children 6-23 Months of Age.” [In eng]. Vaccine 27, no. 32 (Jul 9 2009): 4278-83.

DNA Vaccines: Regulatory Considerations and Safety Aspects.

Myhr, A. I. “DNA Vaccines: Regulatory Considerations and Safety Aspects.” [In eng]. Curr Issues Mol Biol 22 (2017): 79-88.

Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine.

Sotiriadis, A., T. Dagklis, V. Siamanta, K. Chatzigeorgiou, and T. Agorastos. “Increasing Fear of Adverse Effects Drops Intention to Vaccinate after the Introduction of Prophylactic Hpv Vaccine.” [In eng]. Arch Gynecol Obstet 285, no. 6 (Jun 2012): 1719-24.

Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?

Halford, W. P. “Antigenic Breadth: A Missing Ingredient in Hsv-2 Subunit Vaccines?” [In eng]. Expert Rev Vaccines 13, no. 6 (Jun 2014): 691-710.

Safety and Cross-Reactive Immunogenicity of Candidate AS03-Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults.

Jaeger, V. K., H. M. Hoffman, T. van der Poll, H. Tilson, J. Seibert, A. Speziale, G. Junge, et al. “Safety of Vaccinations in Patients with Cryopyrin-Associated Periodic Syndromes: A Prospective Registry Based Study.” [In eng]. Rheumatology (Oxford) 56, no. 9 (Sep 1 2017): 1484-91.

Influenza vaccination of healthcare workers.

Nichol, K. L., and M. Hauge. “Influenza Vaccination of Healthcare Workers.” [In eng]. Infect Control Hosp Epidemiol 18, no. 3 (Mar 1997): 189-94.

Safety of Second-Dose Single-Antigen Varicella Vaccine.

Su, J. R., Z. Leroy, P. W. Lewis, P. Haber, M. Marin, J. Leung, E. J. Woo, and T. T. Shimabukuro. “Safety of Second-Dose Single-Antigen Varicella Vaccine.” [In eng]. Pediatrics 139, no. 3 (Mar 2017).

U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007.

Chang, S., P. M. O’Connor, B. A. Slade, and E. J. Woo. “U.S. Postlicensure Safety Surveillance for Adolescent and Adult Tetanus, Diphtheria and Acellular Pertussis Vaccines: 2005-2007.” [In eng]. Vaccine 31, no. 10 (Feb 27 2013): 1447-52.

The feasibility of universal influenza vaccination for infants and toddlers.

Humiston, S. G., P. G. Szilagyi, M. K. Iwane, S. J. Schaffer, J. Santoli, L. Shone, R. Barth, T. McInerny, and B. Schwartz. “The Feasibility of Universal Influenza Vaccination for Infants and Toddlers.” [In eng]. Arch Pediatr Adolesc Med 158, no. 9 (Sep 2004): 867-74.

UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.

Jones, B. G., R. E. Sealy, X. Zhan, P. J. Freiden, S. L. Surman, J. L. Blanchard, and J. L. Hurwitz. “Uv-Inactivated Vaccinia Virus (Vv) in a Multi-Envelope DNA-Vv-Protein (Dvp) Hiv-1 Vaccine Protects Macaques from Lethal Challenge with Heterologous Shiv.” [In eng]. Vaccine 30, no. 21 (May 2 2012): 3188-95.

Therapeutic vaccines for leishmaniasis.

Khamesipour, A. “Therapeutic Vaccines for Leishmaniasis.” [In eng]. Expert Opin Biol Ther 14, no. 11 (Nov 2014): 1641-9.

Mass psychogenic illness in nationwide in-school vaccination for pandemic influenza A(H1N1) 2009, Taiwan, November 2009-January 2010.

Huang, W. T., C. C. Hsu, P. I. Lee, and J. H. Chuang. “Mass Psychogenic Illness in Nationwide in-School Vaccination for Pandemic Influenza a(H1n1) 2009, Taiwan, November 2009-January 2010.” [In eng]. Euro Surveill 15, no. 21 (May 27 2010): 19575.

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.

Overton, E. T., S. J. Lawrence, E. Wagner, K. Nopora, S. Rosch, P. Young, D. Schmidt, et al. “Immunogenicity and Safety of Three Consecutive Production Lots of the Non Replicating Smallpox Vaccine Mva: A Randomised, Double Blind, Placebo Controlled Phase Iii Trial.” [In eng]. PLoS One 13, no. 4 (2018): e0195897.

Intranasal formulations: promising strategy to deliver vaccines.

Riese, P., P. Sakthivel, S. Trittel, and C. A. Guzman. “Intranasal Formulations: Promising Strategy to Deliver Vaccines.” [In eng]. Expert Opin Drug Deliv 11, no. 10 (Oct 2014): 1619-34.

Deaths following influenza vaccination–background mortality or causal connection?

Kokia, E. S., B. G. Silverman, M. Green, H. Kedem, M. Guindy, and J. Shemer. “Deaths Following Influenza Vaccination–Background Mortality or Causal Connection?” [In eng]. Vaccine 25, no. 51 (Dec 12 2007): 8557-61.

A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.

Kim, D. S., G. Houillon, G. C. Jang, S. H. Cha, S. H. Choi, J. Lee, H. M. Kim, et al. “A Randomized Study of the Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (Je-Cv) in Comparison with Sa14-14-2 Vaccine in Children in the Republic of Korea.” [In eng]. Hum Vaccin Immunother 10, no. 9 (2014): 2656-63.